Compare Bristol-Myers Squibb Co (BMY) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs IQIYI Inc - ADR — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while IQIYI Inc - ADR trades at $1.17 (market cap $1.12B). The key difference: Bristol-Myers Squibb Co is far larger — about 103.8× IQIYI Inc - ADR's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| BMY | IQ | |
|---|---|---|
Market Cap | $116.30B | $1.12B |
Sector | Health | Media |
52-Week High | $62.37 | $2.79 |
52-Week Low | $42.60 | $0.96 |
Enterprise Value | $152.24B | $2.69B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
iQIYI (IQ) trades at $1.13 with no recent price movement, showing mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported Q1 2026 revenue decline of 13% year-over-year to $915.2M, missing expectations, though it beat EPS estimates. Valuation metrics show a high P/E ratio of 144.05 but attractive P/S of 0.29 and P/B of 0.57. Recent leadership changes and AI platform expansion highlight strategic shifts amid challenging fundamentals.
The outlook remains cautious with declining revenues and negative profitability margins creating headwinds. Analyst consensus leans bullish with 50% buy ratings, but execution risks and competitive pressures in China's streaming market pose significant challenges. The stock's current valuation disconnect between high P/E and low price-to-sales metrics suggests potential for recovery if AI initiatives drive growth, but near-term volatility is expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
